

**UNITED STATES DISTRICT COURT  
NORTHERN DISTRICT OF ILLINOIS**

**In re: TESTOSTERONE )  
REPLACEMENT THERAPY ) Case No. 14 CV 1748  
PRODUCTS LIABILITY LITIGATION ) MDL No. 2545  
)**

**JOINT MOTION FOR AN EXTENSION OF TIME FOR THE PARTIES TO FILE  
THEIR PROPOSED CASE MANAGEMENT ORDERS**

Plaintiffs and Defendants respectfully move for an extension of time for the parties to file their proposed case management orders (“CMO”) as required in the Court’s February 1, 2018 minute order. *See* ECF No. 2354. In the order, the Court ordered the parties to confer and submit CMOs by February 16, 2018 for the submission of pretrial materials (1) in existing bellwether cases, and (2) for the CMO 75 cases and the CMO 87 “group 1” and “group 2” cases.

The parties request a one-week extension for the submission of pretrial materials in existing bellwether cases, moving the deadline from February 16 to February 23; and a two-week extension for the submission of pretrial materials for the CMO 75 and 87 cases, moving the deadline from February 16 to March 1. The parties do not seek to amend any other deadlines and this brief extension will not otherwise impact the schedule established by the Court.<sup>1</sup>

Good cause exists for the requested extension. *See* Fed. R. Civ. Pro. 6(b)(1)(A) and 16(b)(4). The pretrial materials cover a number of things including motions in limine, deposition designations and objections, exhibit designations and objections, jury instructions, and voir dire questions. In addition, the parties are required to confer on proposals regarding supplementation

---

<sup>1</sup> The parties are not requesting an extension of time to submit the proposed CMO regarding “a plan to select and work up 100 Actavis cases for all pretrial purposes” required by the same minute order.

of expert reports and any other recurring trial-related issues. While the parties are currently attempting to gather all of this information, additional time is required to file the proposed CMOs.

For the foregoing reasons, the parties jointly request the Court grant the extension.

Dated: February 14, 2018

Respectfully Submitted,

/s/ Trent B. Miracle

Trent B. Miracle  
**Simmons Hanly Conroy LLP**  
One Court Street  
Alton, IL 62002  
Telephone: (618) 259-2222  
Facsimile: (618) 259-2251  
Email: tmiracle@simmonsfirm.com

/s/ Michelle H. Yeary

Michelle Hart Yeary  
**Dechert LLP**  
902 Carnegie Center, Suite 500  
Princeton, NJ 08540  
Telephone: (609) 955-3200  
Facsimile: (609) 955-3259  
Email: michelle.yeary@dechert.com

*Plaintiffs' Co-Lead Counsel*

*Attorney for AbbVie Inc. and Abbott Laboratories*

Andrew K. Solow  
**Arnold & Porter**  
250 West 55<sup>th</sup> Street  
New York, NY 10019  
Telephone: (212) 836-7740  
Facsimile: (212) 836-6776  
Email: andrew.solow@arnoldporter.com

*Attorney for Endo Pharmaceuticals Inc. and Auxilium Pharmaceuticals, Inc.*

Jeffrey D. Geoppinger  
**Ulmer & Berne LLP**  
600 Vine Street, Suite 2800  
Cincinnati, OH 45202  
Telephone: (513) 698-5000  
Facsimile: (513) 698-5001  
Email: jgeoppinger@ulmer.com

*Attorney for Actavis, Inc., Actavis Pharma, Inc., Actavis Laboratories UT, Inc., and Anda, Inc.*

**CERTIFICATE OF SERVICE**

I hereby certify that on February 14, 2018 the foregoing document was filed via the Court's CM/ECF system, which will automatically serve and send email notification of such filing to all registered attorneys of record.

/s/ Michelle H. Yeary  
Michelle Hart Yeary